{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:43:44Z","timestamp":1790401424682,"version":"4.1.0"},"reference-count":58,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2019.4828","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T07:33:39Z","timestamp":1561016019000},"source":"Crossref","is-referenced-by-count":3,"title":["HDAC6\u2011selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma"],"prefix":"10.3892","author":[{"given":"Hye\u2011Rim","family":"Won","sequence":"first","affiliation":[{"name":"College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo\u2011Keun","family":"Yeon","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun\u2011Wook","family":"Ryu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go Woon","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Hee","family":"Kwon","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"key20200713185937_b1-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"key20200713185937_b2-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20200713185937_b3-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/14737140.2014.906904","article-title":"Pomalidomide for the treatment of relapsed-refractory multiple myeloma: A review of biological and clinical data","volume":"14","author":"Offidani","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20200713185937_b4-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/978-3-540-85772-3_11","article-title":"Therapy of relapsed and refractory multiple myeloma","volume":"183","author":"Moehler","year":"2011","journal-title":"Recent Results Cancer Res"},{"key":"key20200713185937_b5-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.6004\/jnccn.2011.0098","article-title":"Management of relapsed and relapsed\/refractory multiple myeloma","volume":"9","author":"Laubach","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"key20200713185937_b6-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1158\/1078-0432.CCR-10-1805","article-title":"Treatment options for relapsed and refractory multiple myeloma","volume":"17","author":"Lonial","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20200713185937_b7-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"key":"key20200713185937_b8-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"key20200713185937_b9-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","article-title":"Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects","volume":"87","author":"Dredge","year":"2002","journal-title":"Br J Cancer"},{"key":"key20200713185937_b10-ijo-55-02-0499","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"key":"key20200713185937_b11-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"key":"key20200713185937_b12-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"key20200713185937_b13-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"key20200713185937_b14-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3109\/10428194.2011.570821","article-title":"Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells","volume":"52","author":"Aldana-Masangkay","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"key20200713185937_b15-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2014-03-559591","article-title":"Lenalidomide inhibits the proliferation of CLL cells via a cereblon\/p21(WAF1\/Cip1)-dependent mechanism independent of functional p53","volume":"124","author":"Fecteau","year":"2014","journal-title":"Blood"},{"key":"key20200713185937_b16-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1517\/13543784.2011.567265","article-title":"Pomalidomide therapy for myeloma","volume":"20","author":"Schey","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"key20200713185937_b17-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/PPO.0b013e31803c72ba","article-title":"Histone deacetylase inhibitors: Biology and mechanism of action","volume":"13","author":"Mehnert","year":"2007","journal-title":"Cancer J"},{"key":"key20200713185937_b18-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.canlet.2009.01.002","article-title":"Development of vorinostat: Current applications and future perspectives for cancer therapy","volume":"280","author":"Richon","year":"2009","journal-title":"Cancer Lett"},{"key":"key20200713185937_b19-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (hdacs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol Oncol"},{"key":"key20200713185937_b20-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: Molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"key20200713185937_b21-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1358\/dot.2009.45.11.1437052","article-title":"Romidepsin for the treatment of cutaneous T-cell lymphoma","volume":"45","author":"Campas-Moya","year":"2009","journal-title":"Drugs Today (Barc)"},{"key":"key20200713185937_b22-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3816\/CLM.2009.n.082","article-title":"Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma","volume":"9","author":"Duvic","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"key20200713185937_b23-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nat Biotechnol"},{"key":"key20200713185937_b24-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1038\/bcj.2014.23","article-title":"Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"4","author":"Siegel","year":"2014","journal-title":"Blood Cancer J"},{"key":"key20200713185937_b25-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3324\/haematol.2009.015495","article-title":"In vitro and in vivo rationale for the triple combination of pano- binostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma","volume":"95","author":"Ocio","year":"2010","journal-title":"Haematologica"},{"key":"key20200713185937_b26-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1200\/JCO.2012.46.7068","article-title":"Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma","volume":"31","author":"San-Miguel","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20200713185937_b27-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2217\/fon-2016-0329","article-title":"Panobinostat for the management of multiple myeloma","volume":"13","author":"Sivaraj","year":"2017","journal-title":"Future Oncol"},{"key":"key20200713185937_b28-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1021\/jm301098e","article-title":"Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth","volume":"55","author":"Bergman","year":"2012","journal-title":"J Med Chem"},{"key":"key20200713185937_b29-ijo-55-02-0499","first-page":"5165","article-title":"Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo","volume":"60","author":"Butler","year":"2000","journal-title":"Cancer Res"},{"key":"key20200713185937_b30-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1021\/cb200134p","article-title":"A novel class of small molecule inhibitors of HDAC6","volume":"7","author":"Inks","year":"2012","journal-title":"ACS Chem Biol"},{"key":"key20200713185937_b31-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"key20200713185937_b32-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.bmcl.2008.12.045","article-title":"Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors","volume":"19","author":"Smil","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"key20200713185937_b33-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1038\/bcj.2015.38","article-title":"Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma","volume":"5","author":"Hideshima","year":"2015","journal-title":"Blood Cancer J"},{"key":"key20200713185937_b34-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20200713185937_b35-ijo-55-02-0499","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood.V122.21.759.759","article-title":"ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor: Interim results of combination therapy with bortezomib in patients with multiple myeloma (MM)","volume":"122","author":"Raje","year":"2013","journal-title":"Blood"},{"key":"key20200713185937_b36-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.bmcl.2010.12.079","article-title":"Structure and property based design, synthesis and biological evaluation of \u03b3-lactam based HDAC inhibitors","volume":"21","author":"Choi","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"key20200713185937_b37-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/carcin\/bgx121","article-title":"A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status","volume":"39","author":"Ryu","year":"2018","journal-title":"Carcinogenesis"},{"key":"key20200713185937_b38-ijo-55-02-0499","first-page":"844","article-title":"The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxali- platin in colorectal cancer cells","volume":"53","author":"Lee","year":"2018","journal-title":"Int J Oncol"},{"key":"key20200713185937_b39-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"key20200713185937_b40-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bmcl.2007.11.047","article-title":"Optimization of biaryl Selective hdac1&2 Inhibitors (SHI-1:2)","volume":"18","author":"Witter","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"key20200713185937_b41-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1365-3024.2009.01134.x","article-title":"Antileishmanial and immunomodulatory activity of Xylopia discreta.","volume":"31","author":"L\u00f3pez","year":"2009","journal-title":"Parasite Immunol"},{"key":"key20200713185937_b42-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"key20200713185937_b43-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"key20200713185937_b44-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"key20200713185937_b45-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.molonc.2015.12.012","article-title":"Essential role of HDAC6 in the regulation of PD-L1 in melanoma","volume":"10","author":"M","year":"2016","journal-title":"Mol Oncol"},{"key":"key20200713185937_b46-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: A novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann Oncol"},{"key":"key20200713185937_b47-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713185937_b48-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/leu.2013.301","article-title":"Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors","volume":"28","author":"Hideshima","year":"2014","journal-title":"Leukemia"},{"key":"key20200713185937_b49-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.13483","article-title":"Impact of XIAP protein levels on the survival of myeloma cells","volume":"94","author":"Desplanques","year":"2009","journal-title":"Haematologica"},{"key":"key20200713185937_b50-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"key":"key20200713185937_b51-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","article-title":"Dutch-Belgian HOVON group; German gmmg Group. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance","volume":"121","author":"Broyl","year":"2013","journal-title":"Blood"},{"key":"key20200713185937_b52-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bjh.12338","article-title":"High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone","volume":"161","author":"Heintel","year":"2013","journal-title":"Br J Haematol"},{"key":"key20200713185937_b53-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","article-title":"A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"key20200713185937_b54-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"key20200713185937_b55-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"key":"key20200713185937_b56-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/1078155215572036","article-title":"Multiple myeloma. Updates for pharmacists in the treatment of relapsed and refractory disease","volume":"22","author":"Ashjian","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"key20200713185937_b57-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/s41467-017-01690-2","article-title":"Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect","volume":"8","author":"Messaoudi","year":"2017","journal-title":"Nat Commun"},{"key":"key20200713185937_b58-ijo-55-02-0499","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:05:12Z","timestamp":1721433912000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2019.4828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":58,"URL":"https:\/\/doi.org\/10.3892\/ijo.2019.4828","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]}}}